| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/22/2000 | EP0987027A1 Physiologically active extract |
| 03/22/2000 | EP0986963A2 Stable, powdery lycopene formulations containing lycopene with a degree of crystallisation of more than 20% |
| 03/22/2000 | EP0986646A1 Ubiquitin conjugation proteins |
| 03/22/2000 | EP0986637A2 Ribozymes cleaving epidermal growth factor receptors |
| 03/22/2000 | EP0986636A1 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
| 03/22/2000 | EP0986570A1 Gemcitabine derivatives |
| 03/22/2000 | EP0986569A1 Process for preparing etoposide |
| 03/22/2000 | EP0986563A1 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo 3,2-d]pyrimidin-4-ones |
| 03/22/2000 | EP0986557A1 Antagonists of gonadotropin releasing hormone |
| 03/22/2000 | EP0986550A1 Antagonists of gonadotropin releasing hormone |
| 03/22/2000 | EP0986544A1 Diphenyl-triazole derivatives and their use as anti-gestative, immuno-suppressant and anti-tumoral agents |
| 03/22/2000 | EP0986400A1 Integrin ligand, human mindin |
| 03/22/2000 | EP0986393A1 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer |
| 03/22/2000 | EP0986391A1 Oxyalkylene phosphate compounds and uses thereof |
| 03/22/2000 | EP0986390A1 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 03/22/2000 | EP0986387A1 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER |
| 03/22/2000 | EP0986385A1 Antagonists of gonadotropin releasing hormone |
| 03/22/2000 | EP0986384A1 Inhibitors of protein isoprenyl transferases |
| 03/22/2000 | EP0986383A1 Method of suppressing tumor growth with combinations of isoprenoids and statins |
| 03/22/2000 | EP0986382A1 Raf kinase inhibitors |
| 03/22/2000 | EP0986381A1 Pharmaceutical compositions for immunosuppression, anticancer and antiviral treatment |
| 03/22/2000 | EP0986378A1 Phorbol esters as anti-neoplastic agents |
| 03/22/2000 | EP0790997B1 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION |
| 03/22/2000 | EP0671912B1 Injectable taxane derivative based compositions |
| 03/22/2000 | CN1248290A Method for induction of apoptotic cell death in malignant cells, through reduction of the RB to apoptosis inducing proteins ratio |
| 03/22/2000 | CN1248288A Nuclear trasfer with differentiated fetal and adult donor cells |
| 03/22/2000 | CN1248253A Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| 03/22/2000 | CN1248177A Coated particles, method of making and using |
| 03/22/2000 | CN1248168A Use of 9,10-secocholesta-5,7,10 (19)-triene-1,3-diol, or alfacacidol |
| 03/22/2000 | CN1247757A Cancer treating medicine capsule |
| 03/22/2000 | CN1247756A Jiangyu injecta for treating malignant tumor |
| 03/22/2000 | CN1050632C Productive Process and use of human anti-tumour alpha type interferon and mutant thereof |
| 03/22/2000 | CN1050631C Preparation for high efficiency anti-tumor gama-type interferon mutant and use thereof |
| 03/21/2000 | US6040338 N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents |
| 03/21/2000 | US6040337 5-demethoxyfumagillol derivatives and processes for preparing the same |
| 03/21/2000 | US6040334 Lovastatin and derivatives |
| 03/21/2000 | US6040330 Pharmaceutical formulations of taxanes |
| 03/21/2000 | US6040329 Substituted indazole analogs |
| 03/21/2000 | US6040326 3-deoxyglucosone production inhibitor |
| 03/21/2000 | US6040323 Phosphatase inhibitors and methods of use thereof |
| 03/21/2000 | US6040321 Enzyme inhibitor treating cancer, inflammation and arthritis, neurodegenerative diseases such as alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases |
| 03/21/2000 | US6040319 cyclization; synthesis of cyclooxygenase-2 (COX) inhibitors such as etoricoxib |
| 03/21/2000 | US6040313 Water-soluble esters of camptothecin compounds |
| 03/21/2000 | US6040312 Formulations and methods of reducing toxicity of antineoplastic agents |
| 03/21/2000 | US6040311 Treating bone disorders for preventing osteoporosis or inhibiting bone resorption in a mammal; treating tumor growth in a mammal |
| 03/21/2000 | US6040304 Formulations and methods of reducing toxicity of antineoplastic agents |
| 03/21/2000 | US6040297 A therapeutic agents treating tumors and retroviral infections including hiv infections |
| 03/21/2000 | US6040294 The compounds have either a sulfhydryl moiety or are reducible disulfides; reducing the side effect of cancer drug |
| 03/21/2000 | US6040289 Active drug treating obesity |
| 03/21/2000 | US6040167 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
| 03/21/2000 | US6040164 Amino acid sequence of enzyme which binds to calmodulin in a calcium-dependent manner and is involved in calcium signalling; for screening agonists and antagonists |
| 03/21/2000 | US6040133 D-enzyme compositions and methods of their use |
| 03/21/2000 | US6039949 Plant extracts obtained by filtration, centrifuging and dialysis |
| 03/21/2000 | US6039948 Amino acid sequences with beta subunit of chorionic gonadotropin endogenous to mammals |
| 03/21/2000 | US6039941 Live vaccine for the treatment of tumor diseases |
| 03/21/2000 | US6039683 Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
| 03/21/2000 | CA2183731C Novel indole derivatives useful to treat estrogen-related neoplasms and disorders |
| 03/17/2000 | CA2282234A1 Antitumor activity strengthening method of crude drugs, composition containing crude drug strengthening antitumor activity, evaluating method of antitumor effectiveness by crude drug treatment, and evaluating method of antitumor effectiveness of crude drug |
| 03/16/2000 | WO2000014257A1 Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| 03/16/2000 | WO2000014256A1 Gene therapy for treatment of cancer |
| 03/16/2000 | WO2000014244A2 Treatment of cervical cancer |
| 03/16/2000 | WO2000014240A2 Attenuated salmonella sp12 mutants as antigen carriers |
| 03/16/2000 | WO2000014231A1 Lim domain protein homolog |
| 03/16/2000 | WO2000014230A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof |
| 03/16/2000 | WO2000014228A1 Neutral amino acid transporter and gene thereof |
| 03/16/2000 | WO2000014209A1 Endothelial cell proliferation inhibitors derived from human prothrombin |
| 03/16/2000 | WO2000014119A2 Bifunctional antibodies and their use in targeting anti-tumour agents |
| 03/16/2000 | WO2000014118A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses |
| 03/16/2000 | WO2000014106A1 Novel bag proteins and nucleic acid molecules encoding them |
| 03/16/2000 | WO2000014083A1 SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
| 03/16/2000 | WO2000014063A1 Therapeutic compounds and methods |
| 03/16/2000 | WO2000013712A2 Methods and compositions for the prevention or treatment of cancer |
| 03/16/2000 | WO2000013700A1 Method of using fetuin to induce apoptosis in cancer cells |
| 03/16/2000 | WO2000013694A1 Gcp |
| 03/16/2000 | WO2000013683A2 Novel nitrophenylaziridine compounds and their use as prodrugs |
| 03/16/2000 | WO2000002897A3 Delta cleavage products and methods based thereon |
| 03/16/2000 | WO2000002881A3 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 03/16/2000 | WO2000000216A3 Use of poxviruses as enhancer of specific immunity |
| 03/16/2000 | WO1999067252A3 Epothilone derivatives and their synthesis and use |
| 03/16/2000 | WO1999065910A9 Fused azepinone cyclin dependent kinase inhibitors |
| 03/16/2000 | WO1999062939A3 Glycoproteins having lipid mobilising properties and therapeutic applications thereof |
| 03/16/2000 | WO1999061471A3 Human transmembrane proteins |
| 03/16/2000 | WO1999058570A3 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis |
| 03/16/2000 | WO1999057151A3 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY |
| 03/16/2000 | WO1999050403A9 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 03/16/2000 | WO1999043636A3 Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs |
| 03/16/2000 | DE19841930A1 Stabile, pulverförmige Lycopin-Formulierungen, enthaltend Lycopin mit einem Kristallinitätsgrad von größer 20% Sturdy, powder-like lycopene formulations comprising lycopene having a degree of crystallinity of greater than 20% |
| 03/16/2000 | CA2345050A1 Method of using fetuin to induce apoptosis in cancer cells |
| 03/16/2000 | CA2343156A1 Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| 03/16/2000 | CA2342963A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses |
| 03/16/2000 | CA2342943A1 Novel nitrophenylaziridine compounds and their use as prodrugs |
| 03/16/2000 | CA2342858A1 Method of screening compounds useful in the treatment of a desease caused by or exacerbated by mpv |
| 03/16/2000 | CA2342027A1 Novel bag proteins and nucleic acid molecules encoding them |
| 03/16/2000 | CA2341777A1 Neutral amino acid transporter and gene thereof |
| 03/16/2000 | CA2341753A1 Bifunctional antibodies and their use in targeting anti-tumour agents |
| 03/16/2000 | CA2341752A1 Methods and compositions for the prevention or treatment of cancer |
| 03/16/2000 | CA2341349A1 Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof |
| 03/16/2000 | CA2341302A1 Lim domain protein homolog |
| 03/16/2000 | CA2340686A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof |
| 03/15/2000 | EP0985415A1 Uracil reductase inactivators |